Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by N Kragh
Evaluating the Cost-Effectiveness of Liraglutide 1.8Mg Versus Lixisenatide 20μg for the Treatment of Type 2 Diabetes Mellitus in the Spanish Setting
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
The Cost-Effectiveness of Dulaglutide Versus Liraglutide in Patients With Type 2 Diabetes Mellitus in Taiwan
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
The Cost-Effectiveness of Canagliflozin Versus Sitagliptin as Third-Line Therapy in Type 2 Diabetes Mellitus (T2dm) in a Canadian Setting
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Assessment of the Key Drivers of Cost-Effectiveness in the Economic Modelling of Canagliflozin (CANA) Versus Glimepiride (GLIM) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost-Effectiveness Analysis of Linagliptin Versus Sulfonylurea as Add-On Treatment to Metformin for the Treatment of Diabetes Mellitus Type 2 Patients in Indonesia
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden
Applied Health Economics and Health Policy
Medicine
Health Policy
Economics
Econometrics
The Effect of Treatment Intensification Assumptions on Estimates of Cost-Effectiveness in Type 2 Diabetes Mellitus (T2dm)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Cost–benefit Comparison of Liraglutide and Sitagliptin in the Treatment of Type 2 Diabetes in Thailand
ClinicoEconomics and Outcomes Research
Health Policy
Economics
Econometrics
Finance
Lixisenatide: Evidence for Its Potential Use in the Treatment of Type 2 Diabetes
Core Evidence
Medicine
Reviews
References
Pharmacology
Cost Effectiveness Evaluation of Canagliflozin in Combination With Metformin in the Treatment of Type 2 Diabetes Mellitus in Poland
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental